- Excellent antimicrobial effects, good for treatment of septic infection, bacterial meningitis

- Minimized tolerance and reduced vomiting when used with other antibiotics


On the 4th, Daewoong Pharmaceutical Co., Ltd (President Lee Jong Wook) released Meropenem, an antibiotic with excellent effects on drug resistance bacterium and a wide scope of antibacterial activity. The antibiotic is classified as beta-lactam, quinolone and aminoglycosides in terms of its structure, effect and symptoms, respectively. Meropenem, a carbapenem antibiotic, is highly recognized as a next generation antibiotic for its excellent effects.

Meropenem has outstanding effects in the treatment of pathogenic pneumonia, infection of peritonitis patients, embolism and bacterial meningitis. Generally, multiple antibiotics were used for the treatment of these conditions, but these would sometimes reduce remedial effect due to increased tolerance. However, meropenem keeps the same remedial effect by minimizing tolerance when used with other antibiotics.

This product also works for cell wall synthesis. Here, the remedial effect is determined by the degree of penetration of the external membrane, and Meropenem shows the merit of having a high penetration. In addition, it also has few side effects such as nausea or vomiting.

With Meropenem, Daewoong Pharmaceutical has obtained a high growth item in the injection antibiotic area, and a growth engine for the future.